Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
de Moura A, Vuagnat P, Renouf B, Pierga JY, Loirat D, Vaflard P, Lafayolle de la Bruyère C, Chaumard-Billotey N, Hajjaji N, Ladoire S, Dabakuyo S, Patsouris A, Frenel JS, Nicolai V, Alexandre M, Dohollou N, Grenier J, Bourien H, Bidard FC.
de Moura A, et al. Among authors: ladoire s.
Sci Rep. 2023 Aug 18;13(1):13427. doi: 10.1038/s41598-023-40569-9.
Sci Rep. 2023.
PMID: 37596388
Free PMC article.